Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor
Naif I AlJohani · 2026
Read Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor by Naif I AlJohani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421350.txt.
Description
AlJohani wrote a letter in 2026 disputing a study that questioned sibling donors in stem cell transplants for myelodysplastic neoplasms. The original Korean study of 391 patients found far higher five-year relapse with matched sibling donors than with unrelated or half-matched donors. Its authors suggested siblings may no longer be the best donor choice under the anti-rejection drug regimen used.
AlJohani argues the comparison is confounded by drug dose, not donor type. Over six in ten sibling recipients got a high dose of antithymocyte globulin, while no half-matched recipient did. Cited evidence shows high doses in sibling transplants raise relapse without cutting graft-versus-host disease, where donor cells attack the patient. The pattern of relapse and side effects fits total immune suppression better than donor source.
Catalog record
| CREATOR | Naif I AlJohani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |